Study S002757

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211(Efocipegtrutide) in Healthy Obese Subjects

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03374241
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 41
Start: 2018-04-04
Primary completion: 2018-09-14
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Obesity
Interventions: BIOLOGICAL:HM15211 or Placebo
Results posted: TRUE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Number of Participants With Adverse Events [1 month]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.